Overview

• A study published in NEJM reports 92% of patients treated solely with dostarlimab remain cancer-free two years post-treatment.
• The immunotherapy regimen eliminates the need for surgery, chemotherapy, or radiation, offering a less invasive alternative for patients.
• Patients with non-rectal cancers, including Stage III tumors and those with lymph node involvement, also showed significant responses, with 64% disease-free at one year.
• The FDA has granted fast track status, and the NCCN has included dostarlimab in guidelines for cancers with targeted genetic mutations.
• Researchers are focusing on long-term survival outcomes and understanding why some patients do not respond to the treatment.